Acurx Pharmaceuticals Q1 2026 Earnings Report

Acurx Pharmaceuticals EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.59
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Acurx Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Acurx Pharmaceuticals Announcement Details

• Quarter: Q1 2026
• Date: 5/12/2026
• Time: Before Market Opens
• Conference Call Date: Tuesday, May 12, 2026
• Conference Call Time: 8:00AM ET

Acurx Pharmaceuticals (NASDAQ:ACXP), headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA). These candidates are engineered to limit bacterial communication and toxin production, potentially enhancing host response while preserving the normal microbiome. The company advances its programs through preclinical studies with the intent to move into first-in-human trials once regulatory filings are secured.

Since its founding in the mid-2010s, Acurx has established collaborations with academic laboratories and industry partners to bolster its drug discovery efforts and accelerate preclinical development. While its operations are predominantly U.S.-based, the company aspires to serve international markets following regulatory approvals. Acurx’s management team comprises professionals with experience in infectious disease research, pharmaceutical development, and regulatory strategy, reflecting a collective commitment to addressing unmet needs in anti‐infective therapy.